Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

579 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Epithelial growth factor receptor interacting agents.
Baselga J, Albanell J. Baselga J, et al. Hematol Oncol Clin North Am. 2002 Oct;16(5):1041-63. doi: 10.1016/s0889-8588(02)00055-2. Hematol Oncol Clin North Am. 2002. PMID: 12512382 Review.
Five-day course of granulocyte colony-stimulating factor in patients with prolonged neutropenia after adjuvant chemotherapy for breast cancer is a safe and cost-effective schedule to maintain dose-intensity.
Ribas A, Albanell J, Bellmunt J, Solé-Calvo LA, Bermejo B, Gallardo E, Vidal R, Vera R, Eres N, Carulla J, Baselga J. Ribas A, et al. Among authors: baselga j. J Clin Oncol. 1996 May;14(5):1573-80. doi: 10.1200/JCO.1996.14.5.1573. J Clin Oncol. 1996. PMID: 8622074 Clinical Trial.
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. Pegram MD, et al. Among authors: baselga jm. J Clin Oncol. 1998 Aug;16(8):2659-71. doi: 10.1200/JCO.1998.16.8.2659. J Clin Oncol. 1998. PMID: 9704716 Clinical Trial.
579 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page